 |
|
Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine
Gu Hyun Jung (Jung GH), Su Jeong You (You SJ)
Clin Exp Pediatr. 2019;62(8):312-316. Published online 2019 Apr 11 DOI: https://doi.org/10.3345/kjp.2019.00017
|
|
Citations to this article as recorded by
 Association between antiseizure medication use and risk of urinary tract infection: A case–control study
Jana Heidemann, Bettina Schmitz, Karel Kostev
Epilepsy & Behavior.2021; 115: 107502. CrossRef Comparative assessment of health-related quality of life with and without anticonvulsant therapy in patients with childhood epilepsy with centrotemporal spikes
Olga An, Lidia Mayumi Nagae, Altyn Aringazina, Steven Parrish Winesett
Journal of International Medical Research.2021; 49(8): 030006052110398. CrossRef Trigeminal Neuralgia: Basic and Clinical Aspects
Erika Ivanna Araya, Rafaela Franco Claudino, Elcio Juliato Piovesan , Juliana Geremias Chichorro
Current Neuropharmacology.2020; 18(2): 109. CrossRef The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects
Laura Orsolini, Simone Pompili, Umberto Volpe
Expert Opinion on Drug Safety.2020; 19(11): 1461. CrossRef Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?
Gwang Cheon Jang
Korean Journal of Pediatrics.2019; 62(8): 299. CrossRef Oxcarbazepine
Reactions Weekly.2019; 1772(1): 260. CrossRef
|